Durable Responses and Low Toxicity After Fast Off-Rate CD19 Chimeric Antigen Receptor-T Therapy in Adults With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia - Concepedia

Concepedia

Publication | Open Access

Durable Responses and Low Toxicity After Fast Off-Rate CD19 Chimeric Antigen Receptor-T Therapy in Adults With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia

DOI Full Paper Access

133

Citations

13

References

2021

Year

Claire Roddie, Juliana Dias, Maeve O’Reilly, Mahnaz Abbasian, Amaia Cadiñanos-Garai, Ketki Vispute, Leticia Bosshard‐Carter, Marina Mitsikakou, Vedika Mehra, Harriet Roddy,

Journal of Clinical Oncology

Abstract

AUTO1 demonstrates a tolerable safety profile, high remission rates, and excellent persistence in r/r adult B-ALL. Preliminary data support further development of AUTO1 as a stand-alone treatment for r/r adult B-ALL.

References

	Year	Citations

Page 1